JIN-YING LUChang, Yi-YaoYi-YaoChangLee, Ting-WeiTing-WeiLeeWu, Ming-HsienMing-HsienWuZHENG-WEI CHENHuang, Yen-TaYen-TaHuangTAI-SHUAN LAIEr, Leay KiawLeay KiawErYEN-HUNG LINVIN-CENT WUCheng, Hao-MinHao-MinChengHSIEN-LI KAOJia-Yin Hou, CharlesCharlesJia-Yin HouKWAN-DUN WUChen, Szu-TahSzu-TahChenLiu, Feng-HsuanFeng-HsuanLiu2023-07-182023-07-1820240929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/633879Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.enAldosterone-to-renin ratio; Anti-hypertensive medications; Centrally acting α-adrenergic agonists; Nondihydropyridine calcium channel blockers; Primary aldosteronism; α-adrenergic receptor blocking agents[SDGs]SDG3journal article10.1016/j.jfma.2023.05.021372910442-s2.0-85161035093